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Abstract: Osteonecrosis of the jaw (ONJ) is a rare treatment related side effect that was 
firstly described in 2002 through a case report in metastatic bone cancer patient treated 
with bisphosphonates (BPs) therapy. ONJ is defined as an eight weeks or longer clinical 
finding of exposed bone in the oral cavity without response to appropriate therapy. The 
diagnosis is mainly clinical but often requires a radiological confirmation with an or-
thopantomography. So it must be made by a dental specialist with sufficient experience 
on ONJ and requires a detailed anamnestic exploration of comorbidities and treatments 
history. In particular, ONJ affects a wide number of oncologic patients treated with BPs 
for bone metastatic cancers and, more recently, with anti-angiogenic drugs. The aim of 
this this paper is to describe diagnosis and classification of this rare but serious side effect 
and its pathophysiology. In particular, we provide a detailed description of clinical evi-
dences upon the relationship between anti-angiogenic drugs and ONJ. Considering the 
evolving of cancer epidemiology with a greater number of cancer surviving patients, this 
side effect always deserves more attention. We conclude that ONJ must be always care-
fully investigated and prevented with a multidisciplinary approach involving oncologist, 
radiation oncologist and skilled dental practitioner when a cancer patient must begin a BP 
or an anti-angiogenic treatment. 
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1. INTRODUCTION 
Osteonecrosis of the jaw (ONJ) was initially de-
scribed through case reporting in patients with meta-
static bone cancer diseases treated with bisphospho-
nates (BPs) therapy. The incidence rates of intravenous 
BPs induced ONJ ranged from 0 % to 27.5%, with a 
mean incidence of 7% [1]. 
The first report describing ONJ ascribed to BPs was 
published in 2003 [2] and the first review about ONJ 
was published by Ruggiero in 2004 [3]. Since the iden-
tification of this problem, a clinical and radiological 
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screening of the oral cavity, made by a dental practi-
tioner, was identified to perform before the starting of 
BPs treatment. This procedure led to the reduction in 
incidence of ONJ appearance.  
In 2007, the definition of BPs-associated ONJ 
(BRONJ) was formulated by the American Society for 
Bone and Mineral Research [4] and recently the special 
committee on medication-related ONJ of the American 
Association of Oral and Maxillofacial Surgeons AA-
OMS suggested changing the name from BRONJ, to 
medication-related ONJ (MRONJ) [5]. 
Various drug groups that promote the osteonecrosis 
of the jaw were identified and they include intravenous 
and oral BPs, Receptor Activator of Nuclear Factor κ B 
(RANK) ligand inhibitors (denosumab) and any angio-
genesis inhibitors [5]. 
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2. DIAGNOSIS 
Patient history and clinical examination are re-
quirement for ONJ diagnosis. An eight weeks or longer 
clinical finding of exposed bone in the oral cavity 
without response to appropriate therapy is the feature 
of ONJ. It can occur in both jaws, with a double inci-
dence, on the mandible and in the jawbone [6]. 
Usually, the lesions are totally asymptomatic for a 
period that could last weeks or months, eventually years, 
and therefore become rarely symptomatic, frequently 
caused by inflammation of adjacent tissues. Once ap-
peared, signs and symptoms include pain, tooth mobili-
ty, mucosal swelling, erythema, ulceration, paresthesia 
or anesthesia of the associated branch of the trigeminal 
nerve [7] that can be compressed from the surrounding 
inflammation [8,9]. These features may occur spontane-
ously or following dentoalveolar surgery; often ONJ 
occur at sites of prior oral surgery [10-15]. Bone 
inflammation and infection are usually present in pa-
tients with advanced ONJ, and appear to be secondary 
events. Intraoral and extra oral fistulae may develop 
when necrotic mandible or maxilla becomes infected. 
The ONJ differential diagnosis includes several clinical 
conditions such as alveolar osteitis, sinusitis, gingivi-
tis/peri-odontitis and periapicalpathosis. The clinical and 
radiological diagnosis of ONJ early stages is often in-
conclusive. Typical radiographic findings of ONJ on 
orthopantomography are increased trabecular density, 
thickening of the mandibular canal or sinus floor cortica-
tion, sequestrum formation and periosteal bone for-
mation. Computed Tomography (CT) and Magnetic 
Resonance Imaging (MRI) also can be used in order to 
allow a better diagnostic definition of ONJ. CT and cone 
beam CT allows improved detection of osseous ONJ 
changes (for example in ONJ, early stages increased tra-
becular density may not be observed on orthopantomog-
raphy but it may be seen on CT scan) [16-20]. MRI re-
sults even more sensitive to orthopantomography and 
CT in assessing bone marrow changes at the early stage 
of ONJ and better shows the soft tissue changes sur-
rounding the osteonecrotic area [21,22]. MRI and CT 
offer similar advantages and are helpful in planning sur-
gery and treatment [21]. 
3. STAGING 
Currently, four distinct clinical stages of MRONJ 
are described (Table 1). When patients are treated with 
BPs or other anti-resorptive medications without any 
clinical or radiographic signs of ONJ, they are consid-
ered in an “at risk” category. Stage 0 category, added in 
the 2009 AAOMS guidelines, includes patients in BPs 
therapy with any clinical or radiographic evidence of 
necrotic bone but with non-specific symptoms or clini-
cal and radiographic abnormalities findings [23, 24]. 
Four AAOMS clinical stages are described in Table 1. 
 
Table 1.  MRONJ clinical stages. 
AAOMS 
stages [5] Definition 
Stage 0 
Patients with no clinical evidence of necrotic bone, 
but with non-specific symptoms or clinical and radio-
graphic findings. 
Stage 1 
Patients with exposed bone who are asymptomatic 
without significant adjacent or regional soft tissue 
inflammation or infection. 
Stage 2 
Patients with exposure of necrotic bone with associat-
ed pain, adjacent or regional soft tissue inflammatory 
swelling or secondary infection. 
Stage 3 
Exposed necrotic bone with associated pain, adjacent 
or regional soft tissue inflammatory swelling or sec-
ondary infection, in addition to a pathologic fracture, 
an extraoral fistula or oral-antral fistula or radiograph-
ic evidence of osteolysis extending to the inferior 
border of the mandible or to maxillary sinus floor. 
 
4. PATHOGENESYS AND RISK FACTORS 
Many authors have tried to explain the etiology of 
ONJ but the exact pathophysiologic mechanism of the 
disease is not fully understood yet. Numerous hypothe-
ses for explaining the development mechanism of ONJ 
are available in literature and include bone turnover 
suppression, bone infections, impaired vascularization, 
immune system malfunction and oral mucosal damages 
[14,25-30]. 
The exclusive location of the bone damage on jaw-
bones, rather than the remnant skeleton, can be ex-
plained by data from studies conducted on animals that 
revealed a more evident bone remodeling and turnover 
in jaws when on BPs treatments [31]. Another hypoth-
esis of the location onset is that jawbones are also fre-
quently submitted to microtrauma, even caused by 
mastication [32]. 
Because ONJ was a lesion of the bone, all the drugs 
that interfere with bone homeostasis have been related 
to this disease, as BPs and denosumab. 
BPs because of their chemical structure bind bone 
matrix with high affinity [33]. Moreover, the non-
nitrogen BPs induce osteoclasts death directly [25], 
whereas the nitrogen-containing BPs inhibit mave-
lonate pathway by inhibition of farnesyl pyrophosphate 
synthetase, resulting into interruption of osteosclasts 
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differentiation and consequently into these cells apop-
tosis [26,27]. Finally, BPs activity leads to bone turno-
ver suppression. 
Another bone homeostasis pathway recently involved 
in ONJ occurrence is RANK and its ligand. Denosumab 
is a humanized monoclonal antibody directed against 
RANK ligand, which plays a critical role in regulating 
bone reabsorption. Given that denosumab plays a potent 
antiresorptive action on bone and ONJ is a result of a 
defective bone homeostasis, ONJ occurrence has been 
described with denosumab treatment [34,35]. 
Since ONJ is an avascular necrosis, there are incom-
ing evidences in literature that angiogenesis is a rele-
vant pathway in ONJ physiopathology. Osteogenesis 
and angiogenesis are closely related processes during 
bone remodeling and repair; it was demonstrated that 
during demineralized bone matrix induced osteogene-
sis, there is a rapid and intense angiogenetic load that is 
vital to the healing and bone induction ability [36]. 
Vascular endothelial growth factor (VEGF) is the es-
sential mediator of angiogenesis and it is essential for 
osteogenic differentiation and bone formation; it has 
been hypothesized that bevacizumab, monoclonal anti-
body directed against circulating VEGF, could com-
promise micro vessel integrity in the jaw and lead to 
subclinical compromise of the bone, causing thereby a 
failure in repairing any eventual oral cavity microtrau-
ma [37]. 
BPs also seem to have an anti-angiogenic effect 
[38,39]: Vincenzi et al. found decreased VEGF circu-
lating levels after the administration of nitrogen-
containing BPs [40]. Angiogenesis and ONJ have re-
cently been linked by several reports about ONJ inci-
dence in cancer patients treated with anti-angiogenic 
agents, as bevacizumab, sunitinib, aflibercept and 
regorafenib [41-44].  
Another potential key point involved in ONJ devel-
opment is the role of VEGF in maintaining immuno-
logic host defense. VEGF receptors are expressed on 
macrophages surface and on monocytes, and their pre-
cursor is responsible for survival, differentiation and 
proliferation of these cells [45]. Blocking VEGF path-
way, anti-angiogenic agents cause the reduction of 
macrophages’ number and activities determining an 
increased risk for infections, followed by tissue necro-
sis [46]. Thus anti-angiogenic drugs, inhibiting VEGF 
pathway, may cause host defense impairment and in-
creased necrosis risk.  
Therefore, there is still much to understand on 
which role impaired vascularization plays in the devel-
opment of ONJ. Below the description of anti-
angiogenic drugs related with ONJ is presented in Ta-
ble 3. 
Considering local risk factors, tooth extraction is the 
most accepted local risk factor for ONJ during BPs 
therapies, since it was often been performed in initial 
reports of ONJ development in literature [47]. Even 
teeth infections are involved in the development of os-
teonecrosis. Some studies demonstrated, in animals, 
that teeth inflammations or infections, with the con-
comitant use of anti-resorptive agents, are potential risk 
factors for ONJ [28,48,49]. BPs, inhibiting bone turno-
ver, interfere with infected tissues clearance: therefore 
if necrotic and flogistic tissues are not removed, they 
should easily progress to chronic osteomyelitis [48]. 
Furthermore, there are reports of bacterial invasion by 
Actinomyces in bisphosphonates, sunitinib and bevaci-
zumab related ONJ [37]. Since Actinomyces is a regu-
lar colonizer of the oral cavity, the Actinomyces-
related infection in ONJ is probably an opportunistic 
infection [50]. Dental screening, made by a specialist 
with sufficient experience of ONJ, in association with 
accurate and continuous oral hygiene, is then recom-
mended for patients before starting any anti-resorptive 
treatments.  
Many authors believe that an immune system mal-
function can promote the development of ONJ. The 
evidence of an ONJ higher risk with concomitant use 
of BPs and steroids or chemotherapy, which deface the 
immune system, sustains their opinion [14,29]. BPs 
plays their effect not only on bone cells but also on mi-
croenvironment’s cells, such as endothelial cells, fibro-
blasts and keratinocytes [51]. The inhibition of these 
cells causes a mucosal damage in the oral cavity, thin-
ning it, and consequently providing an access to the 
underlying bone, supporting bone infection and necro-
sis [52]. 
Known risk factors for developing ONJ, reported in 
Table 2, appear to be BPs treatment, anti-RANKL anti-
body, cancer and its related therapies, in particular anti-
angiogenic agents, invasive dental procedures and oral 
cavity diseases, lifestyle and old age [53,54]. In partic-
ular, BPs duration and intensity treatment influence 
ONJ risk. The risk is higher with parenteral than with 
oral BPs, especially for patients receiving monthly par-
enteral infusion [55,56]. Local risk factors, such as in-
vasive dental procedures or concomitant oral cavity 
diseases increase risk for ONJ [12,57-59]. Dentoalveo-
lar surgery, tooth extraction [12,60], implant placement 
and endodontic or periodontal procedures are known 
risk factors [5]. Other local risk factors are fractures, 
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pre-existing inflammatory dental diseases (i.e. perio-
dontal disease or abscessed teeth) and dental carie 
[12,60,61]. Genetic factors also could play an im-
portant role in the development of MRONJ. Several 
reports described many single nucleotide polymor-
phisms (SNPs) that are associated to genes involved 
with bone turnover, collagen formation or metabolic 
bone diseases [62-64]. Prolonged steroids use [12] and 
mellitus diabetes [65] also seem to increase the inci-
dence of ONJ but additional studies or reports are 
needed to better understand this complex illness. 
 
Table 2.  ONJ developing risk factors. 
Drugs 
Bisphosphonates [1,31,55,56] 
Anti-RANK ligand (denosumab) [34,35] 
Anti-angiogenic drugs (bevacizumab 
[37,66,67,70,71,81-85], sunitinib [42,86,87,73-





Invasive dental procedures (tooth extraction, im-
plant placement, etc) [5,11,12,60] 
Oral cavity disease (teeth or periodontal inflamma-
tions or infections) [60,61] 





Lifestyle (alcohol, tobacco, etc) [14] 
Immune system malfunction [14] 
Comorbidity (mellitus diabetes, rheumatoid arthri-
tis, osteomalacia, etc) [29,65] 
Genetic alterations (SNP on bone structural pro-
tein’s gene) [62-64] 
 
5. FOCUS ON ANTI-ANGIOGENIC DRUGS AND 
ONJ 
5.1. Bevacizumab 
Bevacizumab is a humanized recombinant mono-
clonal antibody that blocks circulating VEGF. Bevaci-
zumab has been related with ONJ by several case re-
ports about patients with bone metastatic breast and 
lung cancers. In 2008, two case reports described for 
the first time ONJ development in metastatic breast 
cancer patients treated with bevacizumab alone, with-
out any history of BPs treatment [37,66]; subsequently, 
two other reports have been described [67,68]. Some 
studies evaluated ONJ occurrence risk in BPs/ bevaci-
zumab combination treatments. A first study, carried 
out by Christodoulou, suggested an increased risk of 
ONJ [69] with the concomitant treatment. Otherwise, 
Guarneri et al. analyzed data from 3,560 patients treat-
ed with bevacizumab for locally recurrent or metastatic 
breast cancer deriving from three clinical trials, AVA-
DO, RIBBON-1, and ATHENA. The ONJ overall inci-
dence with bevacizumab was 0.3% in the blinded phase 
of the two randomized trials (AVADO and RIBBON-
1) and 0.4% in the non-randomized safety study 
ATHENA. This described ONJ incidence is low and 
similar to that described in populations of patients with 
metastatic breast cancer receiving systemic antitumor 
therapies without bevacizumab. It was also noticed that 
in patients submitted to bevacizumab and BPs combi-
nation therapy, the incidence rate of ONJ occurrence 
rose from 0.9 to 2.4%. These results suggest that the 
addiction of bevacizumab could produce only a slight 
increase in ONJ incidence in comparison to BPs treat-
ment alone [41]. Gaurnieri’s data were in accordance 
with a retrospective analysis carried out at Memorial 
Sloan-Kettering Cancer Center by McArthur in 2008, 
who described, in a record of 8,681 patients treated 
with intravenous BPs and/or bevacizumab, a 2% inci-
dence rate of ONJ in patients treated with bevacizumab 
and BPs whereas no cases of ONJ in patients receiving 
bevacizumab alone were described [70]. Another study, 
presented by Lescaille, evaluated the effect of bevaci-
zumab on the severity of ONJ in a cohort of cancer pa-
tients treated with intravenous zoledronic acid. They 
reviewed 42 oncologic patients with ONJ between 
2007 and 2010. This report showed that the combina-
tion of zoledronic acid and bevacizumab was associat-
ed with an increased risk of developing spontaneous 
ONJ; the number of ONJ lesions increased in the com-
bination therapy group compared to the zoledronic acid 
alone group. These results suggested that combination 
between zoledronic acid and bevacizumab could pre-
dispose the development of ONJ [71]. Abovemen-
tioned studies suggest a correlation between anti-
angiogenic agents, alone or in combination with BPs, 
and the development of ONJ, even if data are quite dis-
cordant. Additional information is therefore necessary 
to better understand the correlation between bevaci-
zumab and ONJ. 
5.2. Sunitinib 
Sunitinib is an oral multi-targeted kinase inhibitor 
that inhibits VEGF receptors (VEGFR type 1 and 2), 
platelet-derived growth factor receptors (PDGFR-alpha 
and PDGFR-beta), stem cell factor receptor (KIT), 
FMS-like tyrosine kinase-3 (FLT3), glial cell-line de-
rived neurotrophic factor receptor (RET) and the recep-
tor of macrophage-colony stimulating factor (CSF1R) 
[72]. Sunitinib and ONJ have been linked in a series of 
case reports of patients with bone metastatic renal cell 
carcinoma (RCC) treated with Sunitinib with or 
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Table 3.  List of published papers on ONJ development during anti-angiogenic therapies in cancer patients. 
Anti-angiogenic drug Reference Year of publication Setting 
Bevacizumab 
Estilo et al. [37] 2008 Breast cancer 
Greuter et al. [66] 2008 Breast cancer 
McArthur et al. [70] 2008 Breast and lung cancer 
Serra et al. [81] 2009 Lung cancer 
Guarneri et al. [41] 2010 Breast cancer 
Katsenos et al. [82] 2012 Lung cancer 
Dişel et al. [67] 2012 Colon cancer 
Santos-Silva et al. [83] 2013 Renal cancer 
Sato et al. [84] 2013 Colon cancer 
Magremanne et al. [85] 2013 Glioblastoma multiforme 
Lescaille et al. [71] 2014 Bone metastases 
Sunitinib 
Brunello et al. [42] 2009 Renal cancer 
Hoefert et al. [86] 2010 Renal cancer 
Koch et al. [73] 2011 Renal cancer 
Agrillo et al. [87] 2012 Renal cancer 
Nicolatou-Galitiset al. [75] 2012 Renal cancer 
Fleissig et al. [74] 2012 Renal cancer 
Smidt-Hansen et al. [76] 2013 Renal cancer 
Fusco et al. [77] 2015 Renal cancer 
Aflibercept Ponzetti et al. [43] 2013 Colon cancer 
Regorafenib Antonuzzo et al. [44] 2016 Colon cancer 
Sorafenib 
Beuselink et al. [79] 2012 Renal cancer 
Fusco et al. [77] 2015 Renal cancer 
Garuti et al. [80] 2016 Hepatocellular cancer 
 
without nitrogen-contain BPs [73-77]. A retrospective 
study of 44 RCC patients affected by exposed and non-
exposed ONJ showed that in most cases, they were re-
ceiving, at the time of diagnosis, zoledronic acid in 
93% of patients and anti-angiogenetic agents, mainly 
sunitinib in 80% [77]. This study, in comparison with 
other literature data, suggested a potential role of tar-
geted agents in increasing risk of ONJ. The develop-
ment of sunitinib-related ONJ could mainly be ex-
plained by VEGF signaling pathway interference [12]. 
5.3. Aflibercept 
Aflibercept is a recombinant fusion protein, fused to 
the Fc portion of a human IgG1 immunoglobulin, 
which inhibits VEGF receptors 1 and 2 by binding their 
extracellular domain. It is used in association with 
fluorouracil and irinotecan (FOLFIRI schedule) in pa-
tients with progressive metastatic colorectal cancer af-
ter oxaliplatin-based first line. The first case of ONJ 
occurring was reported in 2013 in a patient treated with 
aflibercept plus FOLFIRI during the expanded-access 
program. This patient developed ONJ after having re-
ceived eleven cycles (nearly six months) of chemother-
apy with anti-angiogenetic agent; he was in risk for 
ONJ because of history of untreated periodontitis and 
episodic previous pyorrhea. He had no history of bone 
metastasis or anti-resorptive agent treatments [43]. 
5.4. Regorafenib 
Regorafenib is a small-molecule multi-kinase inhib-
itor with an anti-angiogenic activity due to its dual tar-
geted VEGFR2-TIE2 tyrosine kinase inhibition. In 
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2016, the first case of ONJ during Regorafenib treat-
ment has been described in literature [44,78] by our 
group. It refers to a heavily pre-treated colorectal can-
cer patient, without any oral known risk factor or anti-
resorptive treatment history, who developed lower jaw 
necrosis after twenty-two months of regorafenib treat-
ment [44,78]. However, this case warrants further vali-
dation on the potential association between Regoraf-
enib and the development of ONJ. 
5.5. Sorafenib 
Sorafenib is an oral multiple tyrosine kinase inhibi-
tor that targets the VEGF receptor family (VEGFR-2 
and VEGFR-3) and platelet-derived growth factor re-
ceptor family (PDGFR-beta and Kit), which play key 
roles in tumor progression and angiogenesis. It is used 
for advanced hepatocellular carcinoma (HCC) and for 
metastatic RCC. Several reports of ONJ occurrence 
during sorafenib therapy in RCC patients, with a medi-
an exposure to sorafenib treatment from 5 to 36 
months, are listed in literature, always used in combi-
nation with BPs for bone metastasis control [77,79]. 
There is instead only one case of HCC patient (three 
months of sorafenib treatment only), without any histo-
ry of BPs treatment but with a previous tooth extraction 
nearly ten months before [80]. 
DISCUSSION AND CONCLUSION 
Osteonecrosis of the jaws (ONJ) is a rare but serious 
complication that emerged in cancer patients treated 
with BPs, denosumab and anti angiogenetic agents. 
Although ONJ pathogenesis is not fully understood 
yet, it is evident that angiogenesis plays a relevant role 
in bone homeostasis and that anti-angiogenetic drugs 
could promote ONJ development.  
In November 2010, the European Medicine Agency 
issued safety alert about ONJ risk during sunitinib or 
bevacizumab treatment [87]. Furthermore, the first 
case-report of ONJ in patients treated with aflibercept 
and in a patient under treatment with regorafenib or 
sorafenib is recently described in literature [43,44,80]. 
The number of case reports of anti-angiogenetic drugs-
related ONJ seems to be growing; this would suggest 
that patients treated with anti-angiogenetic drugs may 
have an increased risk for the development of ONJ. 
We hypothesized that duration of anti-angiogenic 
drugs exposure could be related to ONJ development 
risk, as described for BPs [59]; furthermore, we believe 
that the increasing life expectancy of cancer patients, as 
a result of the growing scientific knowledge and the 
increasing number of available drugs, is leading to the 
revival of serous side effect.  
Therefore, medical oncologists should be aware of 
ONJ potential risk linked to new anti-angiogenic thera-
pies and a preventive oral screening protocol should be 
identified to reduce the risk of ONJ development for 
patients subjected to prolonged treatments with these 
new anti-cancer drugs, alone or in combination with 
BPs. The screening protocol should be composed by a 
radiological and, subsequent, clinical evaluation made 
by a dental care specialist, with sufficient clinical expe-
rience of ONJ in order to identify and remove known 
risk factors before starting treatments. Moreover, more 
attention must be paid for initial and faded symptoms 
in patients submitted to BPs or anti-angiogenic pro-
longed therapies for early diagnosis and prompt treat-
ment. 
A right cooperation between medical oncologists, ra-
diologists and dental care specialist is essential to mini-
mize the burden of this potential serious side effect. 
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SNP = Single Nucleotide Polymorphism 
VEGF = Vascular Endothelial Growth Factor 
VEGFR = Vascular Endothelial Growth Factor Re-
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